HealthMore in Health→
BioNTech, Pfizer Highlight Bispecific Cancer Data as FDA Upheaval Draws Scrutiny
Key Takeaways
- ASCO coverage highlighted BioNTech and Pfizer bispecifics data.
- Rick Pazdur said upheaval at the FDA could create a chance to restructure the agency.
- The story underscores the collision between fast-moving oncology science and regulatory uncertainty.
DE
DT Editorial Team··via statnews.com
